Adnexal Mass - Ultrasound O RADS Based Management

Key Points

• Use standardized O-RADS descriptors rather than vague terms such as 'complex cyst.'
• O-RADS is a malignancy-risk system and does not replace acute torsion evaluation.
• Management depends on category, lesion size, menopausal status, and morphology.
• O-RADS 0 means the examination is incomplete, not low risk.
• O-RADS 4 and 5 lesions warrant expedited gynecologic evaluation and often oncology involvement.
• Normal Doppler flow does not exclude ovarian torsion.
• CA-125 is not a stand-alone diagnostic or screening test for an adnexal mass.
• MRI or specialist ultrasound is useful when morphology remains indeterminate.

Algorithm

1. Determine whether symptoms are acute; if torsion or rupture is suspected, use an emergency gynecologic pathway.
2. Perform high-quality transvaginal and transabdominal ultrasound with Doppler when appropriate.
3. Describe morphology using the O-RADS lexicon and assign the risk category.
4. Apply category-specific management with attention to menopausal status and lesion size.
5. Use short-interval ultrasound, specialist ultrasound, or MRI when further characterization is recommended.
6. Refer O-RADS 4 or 5 lesions for timely gynecologic assessment, often including gynecologic oncology.
7. Select tumor markers only when the imaging and clinical context justify them.
8. Reassess category if lesion morphology changes during surveillance.

Clinical Synopsis & Reasoning

Adnexal masses range from normal physiologic structures and benign cysts to ovarian malignancy. Ultrasound is the primary modality because morphology and Doppler vascularity can characterize most lesions without radiation. The ACR O-RADS ultrasound system provides a standardized lexicon and risk category so that terms such as 'complex cyst' are replaced with more reproducible descriptions. The system is intended for patients with average risk and is primarily a malignancy-risk tool, not an acute-pain algorithm.

Begin by determining whether the ovary and lesion are adequately visualized. Describe maximal size, unilocular or multilocular architecture, simple versus nonsimple fluid, wall and septal smoothness, solid components, papillary projections, acoustic shadowing, and color Doppler flow. Classic benign lesions such as hemorrhagic cyst, endometrioma, dermoid, hydrosalpinx, and paraovarian cyst have specific appearances and management depends on size and menopausal status. O-RADS 0 indicates an incomplete examination; O-RADS 1 is normal; O-RADS 2 is almost certainly benign; categories 3 through 5 represent increasing malignancy risk.

O-RADS should not be used to delay emergency evaluation of ovarian torsion or hemorrhage. A patient with acute severe unilateral pain, nausea, enlarged ovary, peripheral follicles, or reduced flow requires an acute torsion pathway. Conversely, normal Doppler flow does not exclude torsion because dual ovarian blood supply can preserve arterial flow. O-RADS is most useful for incidentally detected or nonacute lesions requiring risk-based follow-up.

Treatment Strategy & Disposition

Management follows category and patient context. O-RADS 2 lesions generally require no follow-up or limited surveillance depending on lesion type, size, and menopausal status. O-RADS 3 lesions are low risk but may warrant follow-up ultrasound, evaluation by an ultrasound specialist, or MRI depending on morphology. O-RADS 4 and 5 lesions carry intermediate or high malignancy risk and generally need gynecologic evaluation, often with gynecologic oncology involvement, and may require MRI or surgical assessment.

Do not interpret CA-125 as a universal screening test for every adnexal mass. It can be elevated in endometriosis, menstruation, pregnancy, fibroids, inflammation, and many nonovarian conditions, while some ovarian cancers have normal values. Tumor markers are selected based on age, morphology, and suspected tumor type and should supplement, not replace, imaging.

MRI is useful when ultrasound remains indeterminate because tissue characteristics, enhancement, diffusion, and dynamic contrast features can improve specificity. O-RADS MRI is a separate standardized system. If a lesion changes size or morphology during surveillance, recategorize rather than automatically continuing the old interval. Any patient with ascites, peritoneal nodularity, metastatic signs, or a high-risk solid vascular lesion requires expedited evaluation rather than routine follow-up.

Epidemiology / Risk Factors

• Adnexal cysts are very common and most are benign.
• Physiologic cysts are expected in premenopausal ovaries.
• Malignancy risk rises with age, postmenopausal status, solid vascular components, and metastatic features.
• Standardized systems reduce unnecessary surgery while improving communication of high-risk findings.

Investigations

Management Themes by Category

Pharmacology

Prognosis / Complications

• Most O-RADS 2 and 3 lesions have benign outcomes with appropriate observation.
• Early referral of high-risk lesions improves coordination of staging-quality surgery when malignancy is present.
• Missed follow-up is a major preventable risk for indeterminate lesions.
• Acute complications such as torsion can threaten ovarian viability even when malignancy risk is low.

Patient Education / Counseling

• Explain the assigned O-RADS category in terms of relative risk and next step rather than giving a category number alone.
• Clarify whether follow-up is needed and exactly when it should occur.
• Seek emergency care for sudden severe pelvic pain, vomiting, syncope, or rapidly increasing abdominal distention.
• Postmenopausal patients should understand why some lesion types receive closer evaluation.
• Reassure patients that many cystic findings are benign and that surveillance is used to avoid unnecessary surgery.

Notes

O-RADS category assignment should be reproducible from the written descriptors. If the report says only 'complex ovarian cyst' without describing the solid components, walls, septations, or vascularity, the referring clinician cannot apply the system reliably.

The management table is not a substitute for clinical context. Acute pain, pregnancy, high-risk genetic status, known cancer, and rapidly changing symptoms can require a different pathway from routine O-RADS surveillance.

References

1. American College of Radiology: O-RADS Ultrasound — Link
2. ACR O-RADS Support: Applicability Criteria and Management — Link